31 results about "Oxybutynine" patented technology

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and / or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation or insertion at a site associated with pain or discomfort upon implantation or insertion. In many embodiments, the therapeutic will be selected from at least one of (i) ketorolac and pharmaceutically acceptable salts thereof (e.g., ketorolac tromethamine) and (ii) 4-diethylamino-2-butynylphenylcyclohexyl glycolate and pharmaceutically acceptable salts thereof (e.g., oxybutynin chloride). Also provided are uses for the implantable or insertable medical devices, which uses comprise reducing pain or discomfort accompanying the implantation or insertion of such devices. Further uses may comprise reducing microbial buildup along the device. Methods for manufacturing implantable or insertable medical devices are also provided.

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising:a step A of obtaining an adhesive agent layer composition comprising oxybutynin hydrochloride as a drug, an acrylic-based polymer and / or a rubber-based polymer as an adhesive base agent, liquid paraffin, a sterol, an organic acid, and a tackifier;a step B of heating the adhesive agent layer composition at a temperature in a range from 55 to 70° C. for 1 to 24 hours; anda step C of cooling the heated adhesive agent layer composition to a temperature lower than room temperature at an average rate of temperature drop of 1 to 20° C. / hour, thereby obtaining the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.

The present invention relates to a dosage unit comprising a water-soluble hydrocolloid and a mucosal surface-coat-forming film, such film including an effective dose of active agent. In the dosage unit slidenafil citrate, nicotine, hydromorphone, oxybutynine or estradiol are used as active agents.

There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. In this combination, the acetylcholinesterase inhibitor (AChEI) is present at a dose that is higher than the maximal recommended dose, per unit form. In particular, the transdermal therapeutic system comprising oxybutynin is in combination with rivastigmine in a transdermal formulation or oral form.

Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.

A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and / or an excipient. The composition is useful for therapy of peripheral neuropathies exemplified by peripheral neuropathies induced by systemic diseases, peripheral neuropathies induced by metabolic diseases, chemotherapy-induced peripheral neuropathies, compression-induced peripheral neuropathies, peripheral neuropathies induced by exposure to dichloroacetate, immune- mediated peripheral neuropathies, peripheral neuropathies induced by infections, and genetically acquired peripheral neuropathies.

The invention relates to the technical field of pharmaceutical preparations, and discloses an oxybutynin transdermal plaster and a preparation method thereof. The transdermal plaster includes a backing layer and a medicated ointment, and the medicated ointment includes the following raw materials in mass percentages: 3-5% of oxybutynin and / or its pharmaceutically acceptable salt, 10-5% of sodium polyacrylate 15%, pre-cross-linked pectin 5‑8%, hypromellose 1‑2%, aluminum glycylate 0.5‑1%, pectinase@ethylcellulose / chitosan microcapsules 1.5‑3.5%, 10-15% of sorbitol, 1-2% of azone lauryl, 10-15% of ethanol, and the balance is water; the pH of the medicated ointment is controlled at 5.0-6.0 by a pH regulator. The oxybutynin transdermal plaster of the present invention has higher air permeability, and can promote the release of oxybutynin by slowly releasing pectinase in the later stage of application, thereby prolonging the duration and duration of the drug effect of the plaster. Application time.

This oxybutynin-containing transdermal absorption preparation is provided with: a support layer which comprises a base fabric and at least a part of which has water-repellent properties; and an adhesive layer which is layered on one surface of the support layer, wherein the adhesive layer contains an adhesive composition that includes oxybutynin or a pharmaceutically acceptable salt thereof, a cholesterol, and a rubber-based adhesive base material. The oxybutynin may be oxybutynin hydrochloride, and the part having water-repellent properties may be formed from a fluorine-containing compound, and the base fabric may be a knitted fabric.

The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder.

The invention provides oxybutynin hydrochloride osmotic pump controlled release tablets and a preparation method thereof. The controlled release tablets are stable in drug release speed in release media of different pH values, and the oxybutynin hydrochloride osmotic pump controlled release tablets are released in a gastrointestinal environment at a basically constant rate, so that the blood concentration of oxybutynin hydrochloride is constantly maintained in an effective concentration range for a long time, a peak valley phenomenon is avoided, the toxic and side effects are reduced, and the bioavailability can be improved.

The invention relates to an oxybutynine ethosomal composition and a preparation method thereof. The oxybutynine ethosomal composition mainly comprises oxybutynine or a pharmaceutically acceptable salt, phospholipid, short-chain alcohol and water. The composition is prepared into a proper preparation form, such as gel and the like. The oxybutynine ethosomal composition is used for transdermal drug delivery and has higher permeation rate and bioavailability than those of an oxybutynine transdermal drug delivery preparation, such as gel and the like.